261 related articles for article (PubMed ID: 12049478)
1. The desferrithiocin (DFT) class of iron chelators: potential as antineoplastic agents.
Kicic A; Chua AC; Baker E
Anticancer Drug Des; 2001; 16(4-5):195-207. PubMed ID: 12049478
[TBL] [Abstract][Full Text] [Related]
2. Desferrithiocin is a more potent antineoplastic agent than desferrioxamine.
Kicic A; Chua AC; Baker E
Br J Pharmacol; 2002 Mar; 135(6):1393-402. PubMed ID: 11906952
[TBL] [Abstract][Full Text] [Related]
3. Development of tridentate iron chelators: from desferrithiocin to ICL670.
Nick H; Acklin P; Lattmann R; Buehlmayer P; Hauffe S; Schupp J; Alberti D
Curr Med Chem; 2003 Jun; 10(12):1065-76. PubMed ID: 12678677
[TBL] [Abstract][Full Text] [Related]
4. Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311.
Chaston TB; Lovejoy DB; Watts RN; Richardson DR
Clin Cancer Res; 2003 Jan; 9(1):402-14. PubMed ID: 12538494
[TBL] [Abstract][Full Text] [Related]
5. Effect of iron chelators on proliferation and iron uptake in hepatoma cells.
Kicic A; Chua AC; Baker E
Cancer; 2001 Dec; 92(12):3093-110. PubMed ID: 11753989
[TBL] [Abstract][Full Text] [Related]
6. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents II: the mechanism of action of ligands derived from salicylaldehyde benzoyl hydrazone and 2-hydroxy-1-naphthylaldehyde benzoyl hydrazone.
Richardson DR; Milnes K
Blood; 1997 Apr; 89(8):3025-38. PubMed ID: 9108424
[TBL] [Abstract][Full Text] [Related]
7. Substituent effects on desferrithiocin and desferrithiocin analogue iron-clearing and toxicity profiles.
Bergeron RJ; Wiegand J; Bharti N; McManis JS
J Med Chem; 2012 Aug; 55(16):7090-103. PubMed ID: 22889170
[TBL] [Abstract][Full Text] [Related]
8. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents III: the effect of the ligands on molecular targets involved in proliferation.
Darnell G; Richardson DR
Blood; 1999 Jul; 94(2):781-92. PubMed ID: 10397746
[TBL] [Abstract][Full Text] [Related]
9. Multidentate pyridinones inhibit the metabolism of nontransferrin-bound iron by hepatocytes and hepatoma cells.
Chua AC; Ingram HA; Raymond KN; Baker E
Eur J Biochem; 2003 Apr; 270(8):1689-98. PubMed ID: 12694182
[TBL] [Abstract][Full Text] [Related]
10. Iron chelators: in vitro inhibitory effect on the liver stage of rodent and human malaria.
Stahel E; Mazier D; Guillouzo A; Miltgen F; Landau I; Mellouk S; Beaudoin RL; Langlois P; Gentilini M
Am J Trop Med Hyg; 1988 Sep; 39(3):236-40. PubMed ID: 3052118
[TBL] [Abstract][Full Text] [Related]
11. Structure-activity relationships among desazadesferrithiocin analogues.
Bergeron RJ; Wiegand J; McManis JS; Weimar WR; Huang G
Adv Exp Med Biol; 2002; 509():167-84. PubMed ID: 12572994
[TBL] [Abstract][Full Text] [Related]
12. Methyl and ethyl ketone analogs of salicylaldehyde isonicotinoyl hydrazone: novel iron chelators with selective antiproliferative action.
Macková E; Hrušková K; Bendová P; Vávrová A; Jansová H; Hašková P; Kovaříková P; Vávrová K; Simůnek T
Chem Biol Interact; 2012 May; 197(2-3):69-79. PubMed ID: 22521999
[TBL] [Abstract][Full Text] [Related]
13. The impact of polyether chain length on the iron clearing efficiency and physiochemical properties of desferrithiocin analogues.
Bergeron RJ; Bharti N; Wiegand J; McManis JS; Singh S; Abboud KA
J Med Chem; 2010 Apr; 53(7):2843-53. PubMed ID: 20232803
[TBL] [Abstract][Full Text] [Related]
14. The desferrithiocin pharmacophore.
Bergeron RJ; Liu CZ; McManis JS; Xia MX; Algee SE; Wiegand J
J Med Chem; 1994 May; 37(10):1411-7. PubMed ID: 8182699
[TBL] [Abstract][Full Text] [Related]
15. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents.
Richardson DR; Tran EH; Ponka P
Blood; 1995 Dec; 86(11):4295-306. PubMed ID: 7492790
[TBL] [Abstract][Full Text] [Related]
16. Iron mobilization, cytoprotection, and inhibition of cell proliferation in normal and transformed rat hepatocyte cultures by the hydroxypyridinone CP411, compared to CP20: a biological and physicochemical study.
Gaboriau F; Chantrel-Groussard K; Rakba N; Loyer P; Pasdeloup N; Hider RC; Brissot P; Lescoat G
Biochem Pharmacol; 2004 Apr; 67(8):1479-87. PubMed ID: 15041465
[TBL] [Abstract][Full Text] [Related]
17. Effects of desferrithiocin and its derivatives on peripheral iron and striatal dopamine and 5-hydroxytryptamine metabolism in the ferrocene-loaded rat.
Dexter DT; Ward RJ; Florence A; Jenner P; Crichton RR
Biochem Pharmacol; 1999 Jul; 58(1):151-5. PubMed ID: 10403528
[TBL] [Abstract][Full Text] [Related]
18. Desazadesmethyldesferrithiocin analogues as orally effective iron chelators.
Bergeron RJ; Wiegand J; Weimar WR; Vinson JR; Bussenius J; Yao GW; McManis JS
J Med Chem; 1999 Jan; 42(1):95-108. PubMed ID: 9888836
[TBL] [Abstract][Full Text] [Related]
19. Desferrithiocin and desferrioxamine B. Cellular pharmacology and storage iron mobilization.
Jin Y; Baquet A; Florence A; Crichton RR; Schneider YJ
Biochem Pharmacol; 1989 Oct; 38(19):3233-40. PubMed ID: 2818622
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of desferrithiocin and its synthetic analogues as orally effective iron chelators.
Bergeron RJ; Wiegand J; Dionis JB; Egli-Karmakka M; Frei J; Huxley-Tencer A; Peter HH
J Med Chem; 1991 Jul; 34(7):2072-8. PubMed ID: 2066978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
